Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC grew its position in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 1.0% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,661 shares of the biopharmaceutical company’s stock after purchasing an additional 563 shares during the period. Gilman Hill Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $3,181,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of BMY. Northwest Financial Advisors purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $27,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $34,000. Turtle Creek Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $40,000. Wetzel Investment Advisors Inc. purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $40,000. Finally, Fairman Group LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $42,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

NYSE:BMY traded down $0.22 during mid-day trading on Tuesday, reaching $42.01. The stock had a trading volume of 5,939,099 shares, compared to its average volume of 15,590,993. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The firm has a market capitalization of $85.16 billion, a price-to-earnings ratio of -13.50, a PEG ratio of 14.02 and a beta of 0.43. Bristol-Myers Squibb has a twelve month low of $39.63 and a twelve month high of $65.38. The business has a 50 day simple moving average of $43.48 and a 200 day simple moving average of $48.37.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.05 earnings per share. On average, analysts expect that Bristol-Myers Squibb will post 0.6 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 5.71%. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Wall Street Analysts Forecast Growth

BMY has been the topic of several recent analyst reports. Barclays dropped their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. BMO Capital Markets dropped their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $60.00.

View Our Latest Stock Analysis on Bristol-Myers Squibb

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

See Also

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.